NasdaqGS - Nasdaq Real Time Price USD
Spyre Therapeutics, Inc. (SYRE)
14.27
+1.41
+(10.93%)
As of 2:59:57 PM EDT. Market Open.
Insider Roster
Insider roster data is derived solely from the last 24 months of Form 3 & Form 4 SEC filings.
| Individual or Entity | Most Recent Transaction | Date | Shares Owned as of Transaction Date |
|---|---|---|---|
| ALBERS JEFFREY W Director | Sale | Nov 6, 2024 | -- |
| BURROWS SCOTT L. Chief Financial Officer | Sale | Sep 3, 2024 | 116,422 |
| FAIRMOUNT FUNDS MANAGEMENT LLC Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Apr 25, 2024 | -- |
| TURTLE CAMERON Chief Executive Officer | Stock Award(Grant) | Feb 15, 2024 | 746,907 |
Related Tickers
DNTH Dianthus Therapeutics, Inc.
19.83
-3.83%
ORKA Oruka Therapeutics, Inc.
9.66
-0.97%
APGE Apogee Therapeutics, Inc.
37.31
-1.32%
TRML Tourmaline Bio, Inc.
15.11
-4.00%
XNCR Xencor, Inc.
8.46
-3.81%
TYRA Tyra Biosciences, Inc.
9.95
-1.19%
IRON Disc Medicine, Inc.
44.45
+0.36%
VRDN Viridian Therapeutics, Inc.
12.57
-1.64%
ABVX ABIVAX Société Anonyme
6.78
-1.02%
CGEM Cullinan Therapeutics, Inc.
7.66
-1.48%